Pancreatic cancer survival has finally doubled in a decade to 13 percent, a fragile but real sign that years of slow, methodical progress are beginning to add up.
November is Pancreatic Cancer Awareness Month and there have been gains in treatment.
Pancreatic cancer has long been one of the toughest cancers to treat. Even as overall cancer survival has improved, progress for pancreatic cancer has come in smaller steps. The story in 2025 is mixed but more encouraging than a decade ago. Survival gains have inched upward, precision drugs have reached small groups of patients with specific tumor features, radiotherapy is getting more accurate, and researchers are learning how to track microscopic disease in the bloodstream after treatment. Here is what is genuinely new and why it matters.
Survival: slow progress and a clearer picture by stage
The five year relative survival rate for pancreatic cancer rose in recent years and then held steady this year at 13 percent. That is still far too low, yet it is more than double the rate from a decade ago, and it reflects real advances in surgery, chemotherapy, radiation, and supportive care.
Looking more closely by stage reveals where patients are gaining the most ground. When the disease is found while it is still confined to the pancreas, five year relative survival is about 44 percent. Once lymph nodes are involved, survival drops to roughly 17 percent. If the cancer has already spread to distant organs, the five year relative survival is just over 3 percent. These stage based numbers explain why researchers are pushing hard to diagnose earlier and to use treatments that can downstage tumors to make surgery possible.
Surgery and chemotherapy: what the latest trials say
For people who can undergo surgery, adjuvant chemotherapy remains essential. The best studied option for fit patients is modified FOLFIRINOX given after surgery. Long term results confirm that this regimen produces longer survival than older single drug approaches and has become the preferred standard for many patients who can tolerate it. Even with strong adjuvant therapy, however, only about one quarter of patients remain disease free at five years, which is why teams are studying earlier use of systemic therapy before surgery.
Neoadjuvant strategies are being refined. A large phase 3 program called PREOPANC has explored combinations given before surgery for borderline resectable and resectable disease. Recent analyses show that not every neoadjuvant recipe improves overall survival, which underscores that timing and regimen choice still matter and that the field is moving from one size fits all toward tailoring by biology and risk.
Radiation therapy: from hard to target to precisely ablative
Radiation for pancreatic tumors has historically been limited by the close proximity of the stomach, duodenum, and other sensitive organs. That is changing as centers adopt magnetic resonance guided radiation therapy and deliver higher, more focused doses in a small number of sessions. Multi institution studies published in 2025 report better local control and a survival advantage for inoperable disease when truly ablative doses are delivered with MRI guidance compared with older techniques. Reviews this year echo the same message. The technology allows clinicians to escalate dose while adapting in real time to organ motion, which appears to translate into better outcomes for carefully selected patients.
Researchers are also testing radioenhancers that are activated by radiation to intensify tumor killing, an idea that is intriguing in locally advanced or borderline resectable disease and now in early phase trials.
Precision medicine: a first approval for a rare fusion
Classic driver mutations in pancreatic ductal adenocarcinoma include KRAS, which appears in the vast majority of cases. Direct KRAS inhibition is finally progressing in early trials, but the biggest clinical win to reach patients so far targets a much rarer alteration. In December 2024 the FDA granted accelerated approval to zenocutuzumab, brand name Bizengri, for people with pancreatic adenocarcinoma whose tumors harbor an NRG1 gene fusion after prior therapy. This is the first drug specifically approved for NRG1 fusion positive pancreatic cancer and it joins the small list of biomarker based treatments available today. The approval was based on response rates in single arm studies and came with the usual requirement for confirmatory trials.
For patients and clinicians, this illustrates the value of broad molecular profiling. While NRG1 fusions are uncommon, identifying them can open the door to a therapy that is now part of the treatment toolbox. Many centers now test for such fusions along with more common alterations to ensure that no targeted option is missed.
Liquid biopsies and minimal residual disease: catching relapse earlier
One of the most important advances of the past two years is the practical use of circulating tumor DNA as a marker of microscopic residual disease after surgery or after first line therapy. Multiple studies presented and published in 2024 and 2025 show that the detection of tumor informed ctDNA after curative intent therapy is a strong predictor of relapse and overall survival. In several cohorts, ctDNA positivity preceded radiographic recurrence by a median of months, which means clinicians can identify high risk patients earlier and consider clinical trials or intensified therapy while disease burden is still low.
Real world programs presented at oncology meetings this year also demonstrated that ctDNA levels can convert from positive to negative with treatment in a meaningful fraction of patients with advanced disease, offering a dynamic way to monitor treatment benefit beyond imaging and CA 19 9 alone. These signals are guiding new trial designs that escalate or de-escalate therapy based on molecular residual disease rather than waiting for visible progression.
Let’s Win Pancreatic Cancer
Vaccines and immunotherapy: early promise and careful optimism
Traditional immune checkpoint inhibitors help only a small slice of pancreatic cancers, mainly those with high microsatellite instability. The field has shifted toward vaccines and combination strategies that try to turn these biologically cold tumors into ones the immune system can recognize. There are two notable storylines in 2025.
First, personalized mRNA neoantigen vaccines continue to show durable T cell responses in small groups of patients after surgery. Investigators at major centers reported sustained immune activity and signs of delayed recurrence in some recipients, with updated mechanistic data published this year in high impact journals. Randomized trials are underway to learn whether these immune responses translate into improved survival at scale.
Second, an off the shelf vaccine approach that targets common KRAS mutations has produced encouraging early results. The AMPLIFY 201 phase 1 study of ELI 002, an amphiphile vaccine designed to train the immune system against mutant KRAS, reported robust CD4 and CD8 responses and signals that stronger immune responses tracked with better outcomes. Investigators have now moved into randomized phase 2 testing in the adjuvant setting. This strategy is attractive because KRAS mutations are present in most pancreatic cancers and a non-personalized vaccine would be faster and potentially less costly to deliver if validated.
These vaccine studies are not practice changing yet, but they represent a meaningful shift from theory to tangible immune activity in people. They also set the stage for combinations with chemotherapy, radiation, or other immune modulators such as CD40 agonists in future trials.
What these trends mean for patients today
The practical takeaway in 2025 is that the care pathway is becoming more individualized. Stage still drives the big decisions, yet within each stage the choices are increasingly shaped by tumor biology and by new tools that measure response more sensitively.
• Testing matters. Comprehensive molecular profiling should be considered for all patients to identify rare yet actionable targets like NRG1 fusions that now have an approved therapy.
• Timing matters. For operable disease, most people will still receive chemotherapy around surgery. Trials continue to explore whether giving more therapy before surgery improves outcomes and for whom that tradeoff is best.
• Precision radiation has a clearer role. At experienced centers, MRI guided ablative radiotherapy is moving the needle for select patients with locally advanced disease by improving local control and in some studies overall survival.
• Monitoring is improving. ctDNA based assays are emerging as a powerful way to detect molecular residual disease months before scans turn positive. This can inform decisions about adjuvant therapy, surveillance intensity, and clinical trial enrollment.
• Immunotherapy is expanding. Beyond the small group with MSI high tumors, vaccine based strategiesare showing immune activity and are now in randomized testing. They are promising but still investigational.
The bottom line
The numbers tell a sober story. Five year survival has plateaued at 13 percent this year after several years of improvement. That pause does not mean the field has stalled. It reflects a cancer that is biologically complex and often diagnosed late. Under the surface, important advances are stacking up. Stage based survival is improving when tumors are found early. Ablative radiation is delivering stronger local control with fewer tradeoffs. The first targeted approval for a rare fusion is already helping a subset of patients who previously had no precise option. Liquid biopsies are teaching doctors how to find persistent disease earlier and to tailor therapy in real time. Vaccine based immunotherapy has moved from theory to measurable immune responses with randomized trials in progress.
Pancreatic cancer is not solved, but the toolbox is bigger and more refined than it was even two years ago. For patients and families, the most actionable steps are to seek care at centers with multidisciplinary expertise, ask about comprehensive genomic testing, and inquire whether ctDNA monitoring and modern radiotherapy options are appropriate. For the community at large, continued participation in clinical trials is the fastest path to turning these early gains into broad and durable improvements in survival.
12 cancer signs people ignore until it’s too late
Every year, thousands of cancers go unnoticed, not because they hide well, but because their earliest warnings look like everyday life.
We all have those little health quirks we brush off—feeling extra tired, weird stomach aches, or random weight changes. Most of the time, it’s nothing serious, right? But sometimes, those quiet changes are your body waving a red flag.
The tricky part is that cancer doesn’t always arrive loudly—it often whispers. And with the American Cancer Society projecting about 2 million new cancer cases and over 618,000 related deaths in 2025, paying attention could truly save lives. So, this isn’t about panic; it’s about paying attention, because a little awareness can truly make a difference.
